Cardax Appoints Global Healthcare Executive as Independent Director

Sigue a La Raza en Facebook

Brings Experience Across Pharma, Biotech, and Consumer Health

HONOLULU–(BUSINESS WIRE)–$CDXI #astaxanthin–Cardax, Inc. (“Cardax”) (OTCQB:CDXI) announced today the appointment of
Michele Galen, an attorney and former Chief Communications Officer for
both Novartis AG and Shire plc, as an independent member of its Board of
Directors. Ms. Galen will join current Chairman and independent director
George Bickerstaff, independent director Terence A. Kelly, PhD, and
Cardax CEO David G. Watumull on the Cardax Board. The appointment was
made on January 4, 2017.

“Michele brings highly successful senior management and communications
experience from Novartis, Shire, and leading venture capital firm MPM
Capital to the Cardax Board,” said Chairman George Bickerstaff.
“Combined with her experience as a journalist and lawyer, Michele offers
a unique perspective that will further contribute to the achievement of
our strategy.”

“Michele’s broad background, in particular across consumer health and
pharmaceutical commercialization, provides an ideal skill set for Cardax
as it commercializes ZanthoSyn™, its safe anti-inflammatory for general
health, and develops CDX-085, its superior second generation product,”
said CEO David G. Watumull. “We are delighted to welcome Michele to the
Cardax Board.”

About Michele Galen

Michele Galen is a strategic advisor to firms across pharmaceuticals,
biotech, health start-ups and global health. Ms. Galen served as Global
Head, Communications and Public Affairs, for Shire plc, serving as the
lead communications and public affairs advisor on the $32 billion
successful acquisition and integration of Baxalta. Previously, Ms. Galen
led Global Communications in Switzerland for Novartis AG, where she
spent 14 years in positions of increasing responsibility and served on
several management boards. Earlier, Ms. Galen served as chief marketing
officer for MPM Capital, Managing Director for public relations firm
Burson-Marsteller, Legal Affairs Editor for Business Week magazine, and
an attorney with Skadden, Arps, Slate, Meagher & Flom LLP. Ms. Galen is
currently a board member for nonprofit Global Oncology and for MK&A, a
global healthcare consulting firm. Ms. Galen received a B.A. from George
Washington University, M.S. from the Columbia University Graduate School
of Journalism, and J.D. from New York University School of Law.

About Cardax, Inc.

Cardax, Inc. devotes substantially all of its efforts to developing and
commercializing safe anti-inflammatory dietary supplements and drugs.
Cardax is initially focusing on astaxanthin, which is a powerful and
safe naturally occurring anti-inflammatory without the side effects of
currently marketed anti-inflammatories. The safety and efficacy of
Cardax’s products have not been directly evaluated in clinical trials or
confirmed by the FDA.

Safe Harbor

This release may contain certain forward-looking statements regarding
our prospective performance and strategies within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. We intend such
forward-looking statements to be covered by the safe harbor provisions
for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995, and are including this statement for
purposes of said safe harbor provisions. Forward-looking statements,
which are based on certain assumptions and describe future plans,
strategies, and expectations of our company, are generally identified by
use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,”
“plan,” “project,” “seek,” “strive,” “try,” or future or conditional
verbs such as “could,” “may,” “should,” “will,” “would,” or similar
expressions. Our ability to predict results or the actual effects of our
plans or strategies is inherently uncertain. Accordingly, actual results
may differ materially from anticipated results. Some of the factors that
could cause our actual results to differ from our expectations or
beliefs include, without limitation, the risks discussed from time to
time in our filings with the Securities and Exchange Commission. Readers
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release. Except as
required by applicable law or regulation, we undertake no obligation to
update these forward-looking statements to reflect events or
circumstances that occur after the date on which such statements were
made.

Contacts

Cardax, Inc.
Janice Kam, 1-808-457-1400
press@cardaxpharma.com